Larimar Therapeutics (LRMR) Expected to Release Earnings on Thursday

Larimar Therapeutics (NASDAQ:LRMR) is anticipated to post its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to announce earnings of ($0.39) per share for the quarter. Investors can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, August 4, 2026 at 7:00 AM ET.

Larimar Therapeutics (NASDAQ:LRMR) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.08. On average, analysts expect Larimar Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Larimar Therapeutics Stock Up 7.5%

Shares of LRMR stock opened at $4.31 on Wednesday. The stock has a market cap of $447.72 million, a price-to-earnings ratio of -2.21 and a beta of 0.81. Larimar Therapeutics has a fifty-two week low of $2.71 and a fifty-two week high of $6.42. The firm’s 50 day moving average price is $3.67 and its two-hundred day moving average price is $4.00.

Insider Transactions at Larimar Therapeutics

In other news, Director Thomas Edward Hamilton acquired 50,000 shares of the business’s stock in a transaction on Monday, July 6th. The shares were purchased at an average price of $3.34 per share, for a total transaction of $167,000.00. Following the acquisition, the director directly owned 714,798 shares of the company’s stock, valued at $2,387,425.32. This represents a 7.52% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 4.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets increased its stake in Larimar Therapeutics by 75.8% during the third quarter. BNP Paribas Financial Markets now owns 10,146 shares of the company’s stock valued at $33,000 after purchasing an additional 4,376 shares during the last quarter. Coldstream Capital Management Inc. bought a new position in shares of Larimar Therapeutics in the 3rd quarter worth about $57,000. Commonwealth Equity Services LLC bought a new position in shares of Larimar Therapeutics in the 4th quarter worth about $87,000. Price T Rowe Associates Inc. MD lifted its position in shares of Larimar Therapeutics by 26.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 29,008 shares of the company’s stock worth $111,000 after buying an additional 6,038 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new position in shares of Larimar Therapeutics in the 4th quarter valued at about $116,000. 91.92% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Robert W. Baird cut their target price on shares of Larimar Therapeutics from $7.00 to $5.00 and set an “outperform” rating on the stock in a research note on Tuesday, June 30th. JPMorgan Chase & Co. began coverage on shares of Larimar Therapeutics in a report on Wednesday, May 27th. They set an “overweight” rating and a $9.00 target price on the stock. HC Wainwright began coverage on shares of Larimar Therapeutics in a research report on Thursday, July 2nd. They set a “buy” rating and a $10.00 price target for the company. Citigroup reiterated a “buy” rating on shares of Larimar Therapeutics in a report on Tuesday, June 30th. Finally, Wall Street Zen raised Larimar Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Three research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $12.57.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc is based in Bala Cynwyd, Pennsylvania.